SLEEP, held in San Antonio, Texas from June 8–12, 2019, is the annual meeting of the Associated Professional Sleep Societies, LLC (APSS), which is a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS). The annual conference provides evidence-based education to advance the science and clinical practice of sleep disorders, disseminates cutting-edge sleep and circadian research, promotes the translation of basic science into clinical practice, and provides career development opportunities at all levels.
The director of the center for circadian and sleep medicine at Northwestern University spoke about the importance of recognizing insomnia as a clinical diagnosis since it affects patients 24-hours a day, not just during sleep.
Investigators noted that, when considered with efficacy findings in narcolepsy, pitolisant has a favorable risk-benefit profile representative of advancement in the treatment of excessive daytime sleepiness and cataplexy in adult patients.
The autonomic disorders and sleep medicine specialist at Stanford University spoke about the overlap of autonomic disorders in sleep medicine, an often underrepresented portion of the sleep medicine field.
The investigational dual-orexin antagonist from Eisai was significantly better at reducing Insomnia Severity Index-measured symptom severity in more than 1000 adults with insomnia in 2 phase 3 studies.
The efficacy of CBT using the American Academy of Sleep Medicine (AASM) SleepTM platform has been shown to be similarly efficacious to face-to-face physician encounters in 30 adults with chronic insomnia.